ELEVAI LABS INC. - COMMON STOCK

Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024

26 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

14 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm

29 May 2024 08:00:00 By Nasdaq GlobeNewswire

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference

22 May 2024 15:15:00 By Nasdaq GlobeNewswire

Elevai Labs Inc. Reports First Quarter 2024 Financial Results

15 May 2024 15:30:31 By Nasdaq GlobeNewswire

Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity

02 May 2024 07:30:00 By Nasdaq GlobeNewswire

Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare

01 May 2024 15:00:25 By Nasdaq GlobeNewswire

Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

01 May 2024 08:00:00 By Nasdaq GlobeNewswire

Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments

29 Apr 2024 08:46:12 By Nasdaq GlobeNewswire

ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results

29 Mar 2024 11:00:00 By Nasdaq GlobeNewswire

Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market

18 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office

24 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach

17 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology

16 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences

02 Jan 2024 08:15:00 By Nasdaq GlobeNewswire

Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023

11 Dec 2023 08:15:00 By Nasdaq GlobeNewswire

ELEVAI Labs, Inc. Expands International Distribution into Europe

07 Dec 2023 08:41:56 By Nasdaq GlobeNewswire

Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products

29 Nov 2023 08:00:00 By Nasdaq GlobeNewswire